Re: 'Use of androgen deprivation therapy in prostate cancer: indications and prevalence' by Connolly et al.

about

Re: 'Use of androgen deprivation therapy in prostate cancer: indications and prevalence' by Connolly et al.

Item

http://www.wikidata.org/entity/Q42540042

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Re: 'Use of androgen deprivati ...... prevalence' by Connolly et al.

@en

Re: 'Use of androgen deprivati ...... prevalence' by Connolly et al.

@nl

type

Item

label

Re: 'Use of androgen deprivati ...... prevalence' by Connolly et al.

@en

Re: 'Use of androgen deprivati ...... prevalence' by Connolly et al.

@nl

prefLabel

Re: 'Use of androgen deprivati ...... prevalence' by Connolly et al.

@en

Re: 'Use of androgen deprivati ...... prevalence' by Connolly et al.

@nl

P1476

Re: 'Use of androgen deprivati ...... prevalence' by Connolly et al.

@en

P2093

Bo-Eric Persson

http://www.w3.org/2001/XMLSchema#string

P2860

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.

A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

Use of androgen deprivation therapy in prostate cancer: indications and prevalence.

Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix.

Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.

P304

795

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJA.2012.53

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230697836

http://www.w3.org/2001/XMLSchema#string

P698

22902910

http://www.w3.org/2001/XMLSchema#string

P932

3734989

http://www.w3.org/2001/XMLSchema#string